Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FECHT Trial
NCT06478719Phase 2Recruiting
- Sponsor
- Far East Bio-Tec Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FB-1603 in hepatocellular carcinoma (HCC), sponsored by Far East Bio-Tec Co., Ltd.. Started Jun 2024; status: recruiting.
02
Drugs
FB-1603
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06478719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478719.